Today's earnings

Discussion in 'Ironwood Pharmaceuticals' started by Anonymous, Nov 4, 2014 at 1:51 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Any thoughts on how earning will look today after the bell?
     

  2. Anonymous

    Anonymous Guest

    Looks down, revenue was light.

    I thought with 79 mil in sales revenue would be higher the street also.
     
  3. Anonymous

    Anonymous Guest

    And they area burning through too much cash. This doesn't look good.
     
  4. Anonymous

    Anonymous Guest

    Linzess is starting to not look like a billion $ brand. The street is catching on to this tied to high cash burn and ridiculous expenses with the co-promote. No positive signals for analysts to base a positive thesis on.
     
  5. Anonymous

    Anonymous Guest

    Stock is tanking, down $1 since the news. Wall Street agrees with you
     
  6. Anonymous

    Anonymous Guest

    Hows that stock price doing now???
     
  7. Anonymous

    Anonymous Guest

    About to tank again, always does once it hits 15. Wall Street ain't sold on this chloride channel activator, Sucampo stock is kicking ass though.

    The death march continues...
     
  8. Anonymous

    Anonymous Guest

    Lmao....drug profitable in two years iw slated to be profitable by end of 2015. Surpassed amitiza share in less than two years, took them 7. 13 14 15 20 whatever we got our shares at $8.50 as long as it's above that, whatever.
     
  9. Anonymous

    Anonymous Guest

    Please stop using the managers term " profitable".. It's a joke and completely misleading.. The company is losing 230 million dollars a year.. There is nothing even close to profitable at irwd ... You are simply twisting the truth ... Please stop using that term as it does not apply
     
  10. Anonymous

    Anonymous Guest

    It's lower today than it was in 2012 that's how
     
  11. Anonymous

    Anonymous Guest

    If you can read a balance sheet you will know that it is impossible for IRWD to be profitable by end of 2015. Also, as with many biotech stocks profitability is not the only driver of valuation. One of the biggest drivers is capital allocation. IRWD has not shown any discipline with their allocation of capital on the R&D and commercial side. This coupled with Linzess starting to look like less than a billion dollar brand will continue to weigh heavily on the stock. A $16 stock value would be generous at this point.
     
  12. Anonymous

    Anonymous Guest

    IRWD is not profitable because the excellence, once attributed to the original Woodies, is gone.
    When the best and the brightest have left the company, there is little left.
    The brand will suffer, and the general success of the company will suffer. And of course, this translates into the decline of stock. Capital allocation can no longer keep up.
    The departure of the original group of Woodies has hurt IRWD immeasurably. Raising the bar for any new hires may help things. Sadly, the original Woodies cannot be replaced any time soon.
     
  13. Anonymous

    Anonymous Guest

    Yawn..... No one cares. Pipeline and additional indications look good. They have added another week vaca and yearly stock grants. 15 a share when we are not yet profitable. I will take it. No job is perfect but we are paid great salaries. It's year two our drug is profitable, no company is profitable when they have been spending money for 15 years and only generating it for two. I'll take the 15 valuation now with our only drug and wait it out. All you neighsayers either didn't get the job or work for a competitor. If you don't, then just leave. Plenty of people would kill for this job.